Compare Incyte Corporation (INCY) vs TORM plc (TRMD) Price & Performance

Incyte CorporationTrade

TORM plcTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs TORM plc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while TORM plc trades at $28.35 (market cap $2.93B). The key difference: Incyte Corporation is far larger — about 8.4× TORM plc's market cap, and TORM plc pays a 9.77% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

	INCY	TRMD
Market Cap	$24.54B	$2.93B
Sector	Health	Technology
52-Week High	$129.93	$34.87
52-Week Low	$81.61	$18.77
Enterprise Value	$20.04B	$3.82B
Dividend Yield	—	9.77%

View details →View details →

Returns comparison

Trailing returns across standard periods

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About TORM plc

TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.